Scott + Scott, LLP Reminds Investors of Monday, March 14, 2016 Deadline to File Lead Plaintiff Papers in Esperion Therapeutic...
March 02 2016 - 2:15PM
Business Wire
Scott + Scott, Attorneys at Law, LLP, a global investor rights
law firm, reminds investors that Monday, March 14, 2016 is the
deadline for filing lead plaintiff papers in the securities lawsuit
against Esperion Therapeutics, Inc. (ESPR). Esperion investors are
encouraged to contact Scott + Scott at (866) 326-5057 or
email gjohnson@scott-scott.com to discuss their legal rights.
About the Lawsuit
Esperion is a pharmaceutical company that focuses on developing
and commercializing oral low-density lipoprotein cholesterol
("LDL-cholesterol") lowering therapies. The securities lawsuit
alleges that Esperion issued a press release on August 17, 2015
about its lead product candidate, ETC-1002, that was false and was
in conflict with a September 28, 2015 press release.
On August 17, 2015, Esperion stated that it "remains on track to
initiate the ETC-1002 Phase 3 development program by the end of
2015" and that, "[b]ased on feedback from the FDA, approval of
ETC-1002 in the HeFH and ASCVD patient populations will not require
the completion of a cardiovascular outcomes trial (CVOT)."
On September 28, 2015, Esperion stated that "[f]or patients on
maximally tolerated statin therapy who require additional LDL-C
lowering, Esperion will plan to conduct efficacy and long-term
safety trials. FDA has encouraged the Company to initiate a
cardiovascular outcomes trial promptly … since any concern
regarding the benefit/risk assessment of ETC-1002 could necessitate
a completed cardiovascular outcomes trial before approval."
On this news, shares of the Company's stock declined $16.76 per
share, or over 47%, to close on September 29, 2015 at $18.33 per
share.
What you can do
If you purchased shares of Esperion stock, you may have legal
claims against the Company. If you wish to discuss the
investigation, or have questions about your legal rights, please
contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by
telephone at (866) 326-5057 or by email at gjohnson@scott-scott.com
or jhalloran@scott-scott.com.
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major
securities, antitrust, and employee retirement plan actions
throughout the United States. The firm has offices in New York,
London, Connecticut, California and Ohio.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160302006337/en/
Scott + Scott, Attorneys at Law, LLPGeoffrey M. Johnson, Esq.,
216-229-6088Toll-free: 866-326-5057orJoseph Halloran, Esq.,
646-582-0121
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024